Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Pfizer Declares First-Quarter 2021 Dividend

Business Wire December 11, 2020

Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.

Business Wire December 10, 2020

Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine

Business Wire December 10, 2020

Health Canada approves Pfizer-BioNTech COVID-19 vaccine

Oliver Gray December 9, 2020

U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer's Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older

Business Wire December 8, 2020

Stocks Fall as Investors Weigh Stimulus Hopes, COVID Rises

Livemoney December 8, 2020

PostEra enters a multi-year strategic partnership with Pfizer Inc. to advance machine learning for Drug Discovery

Canada NewsWire December 7, 2020

Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody (PF-06863135) in Multiple Myeloma

Business Wire December 7, 2020

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy

Business Wire December 7, 2020

Vaccine Concerns Drag S&P From Record Perch

Livemoney December 3, 2020

Futures Fade After December Starts Strong

Livemoney December 2, 2020

ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions of HIV with 'HIV in View'--a first-of-its-kind online HIV photography gallery

PR Newswire December 1, 2020

Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors

Business Wire November 23, 2020

Dow Futures Sink amid Talk of More COVID Restrictions

Livemoney November 20, 2020

Results from Phase 3 CROWN Trial of Pfizer's LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine

Business Wire November 19, 2020

Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints

Business Wire November 18, 2020

Scott+Scott Attorneys at Law LLP Investigates Pfizer, Inc.'s (PFE) Directors and Officers for Breach of Fiduciary Duties

Business Wire November 17, 2020

Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan

Business Wire November 16, 2020

Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYNDAMAX® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Compared to VYNDAQEL 20 mg

Business Wire November 12, 2020

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire November 11, 2020